



1 AGCATCCTGA GTAATAGTG GCCTGGGCGG GAGCAGGCGA GGTGGCGGGA GCGTGTGGA CCAGGAGGAG CGCTTTCCAC AGGCGCTGTG GACGGGGGTG
TCGTAGGACT CATTACTCAC CGGACCGCGC CTCGTCCGCT CCACCGGCGT CGGCACACCT GGTCTCTCTC GCGAAGGTG TCCCGGACAC CTGCCCCCAC
1 M S G L G R S R R G G R S R V D Q E E R F P Q G L W T G V

101 GCTATGAGAT CCTGCCCGGA AGAGCAGTAC TGGATCCTC TGCTGGGTAC CTGCATGTCC TGC AAAACA TTTGCAACCA TCAGAGCCAG CGCAGCTGTG
CGATCTCTA GGACGGGGT TCTCGTCATG ACCTAGGAG ACAGACCATG GACGTACAGG ACGTTTGTGTTTAACTTGT AAACGTTGTT AGTCTCGTGC CGGTGGACAC
30 A M R S C P E E Q Y W D P L L G T C M S C K T I C N H Q S Q R T C A

201 CAGCCTTCTG CAGGTCACTC AGCTGCCGGA AGGACCAAGG CAAGTTCTAT GACCATCTCC TGAGGGACTG CATCAGCTGT GCCTCCATCT GTGGACAGCA
GTCCGAAGAC GTCCAGTGAG TCGACGGCGT TCCTCGTTCC GTTCAAGATA CTGCTAGAGG ACTCCCTGAC GTAGTCGACA CGGAGGTAGA CACCTGTCTG
64 A F C R S L S C R K E Q G K F Y D H L L R D C I S C A S I C G Q H

301 CCCTAAGCAA TGTGCATACT TCTGTGAGAA CAAGCTCAGG AGCCAGTGA ACCTTCCACC AGAGCTCAGG AGACAGCGGA GTGGAGAAGT TGAACAACAT
GGGATTCGTT ACACGTATGA AGACACTCTT GTTCAGTCC TCGGTCACT TGGAGGTGG TCTCGAGTCC TCTGTGCTCT CACTCTTCA ACTTTTGTTA
97 P K Q C A Y F C E N K L R S P V N L P P E L R R Q R S G E V E N N

401 TCAGACAACCT CGGAAGGTA CCAAGGATTG GAGCACAGAG GGTCAAGAC AGTCCAGCT CTCGCCGGGC TGAAGTGTAG TGCAGATCAG GTGGCCCTGG
AGTCTGTGA GCCTTCCAT GGTTCCTAAC CTCGTGCTC CTCAGTCTTG TTCAGTCTGA GAGGGCCCCG ACTTCAGTCT ACCTCTAGTC CACCGGAGCC
130 S D N S G R Y Q G L E H R G S E A S P A L P G L K L S A D Q V A L V

501 TCTACAGCAC GCTGGGGCTC TGCCTGTGTG CCGTCTCTCTG CTGCTTCTCTG GTGGCGGTGG CCTGCTTCTCT CAAGAAGAGG GGGATCCCT GCTCCTGCCA
AGATGTCTG CGACCCCGAG ACGGACACAC GGCAGGAGAC GAGCAAGGAC CACCGCCACC GAGCAAGGA GTTCTTCTCC CCCCTAGGGA CGAGGACGGT
164 Y S T L G L C L C A V L C C F L V A V A C F L K K R G D P C S C Q

601 GCCCGCTCA AGGCCCGTC AAAGTCCGGC CAAGTCTTCC CAGGATCAG CGATGGAAGC CGGAGGCCCT GTGAGCACAT CCCCGAGCC AGTGGAGACC
CGGGCGAGT TCCGGGCGAG TTTCAAGCGG GTTCAGAAGG GTCTAGTGC GCTACCTTCG GCGTCTGGA CACTCGTGA GGGGCTCGG TCACCTCTGG
197 P R S R P R Q S P A K S S Q D H A M E A G S P V S T S P E P V E T

701 TGCAGCTTCT GCTTCCCTGA GTGCAGGGG CCCACGAGG AGAGCGCAGT CAGCCTGGG ACCCCGACC CCACCTGTGC TGAAGGTGG GGGTCCACA
ACGTCGAAGA CGAAGGACT CAGTCCCGC GGTGCGTCC TCTCGGTCA GTGCGGACCC TGGGGCTGG GGTGAACAGG ACCTTCCACC CCCACGGTGT
230 C S F C F P E C R A P T Q E S A V T P G T P D P T C A G R W G C H T

801 CCAGGACCAC AGTCTCTGAG CCTTGCCAC ACATCCGAGA CAGTGGCCTT GGCATTGTGT GTGTGCTCTG CCAGGAGGGG GGGCCAGGTG CATAAATGGG
GGTCTGGT TCAGGAGTC GGAACGGGTG TGTAGGTCT GTACCGGAA CCGTAACACA CACAGGAGG GGTCTCTCC CCGGTCCAC GTATTTACCC
264 R T T V L Q P C P H I P D S G L G I V C V P A Q E G G P G A O


FIG. 1A

USES OF AGONISTS AND ANTAGONISTS TO MODULATE
ACTIVITY OF TNF-RELATED MOLECULES

Sheet 2 of 29

```
901 GGTGAGGAG GGAAGGAGG AGGAGAGAG ATGGAGAGGA GGGAGAGAG AAAGAGAGGT GGGAGAGAGG GAGAGAGATA TGAGAGAGAG GAGACAGAGG
    CCAGTCCCTC CTTTCCCTCC TCCCTCTCTC TACCTCTCTC CCCCCTCTCC TTTCTCTCCA CCCCCTCTCC CTCTCTCTAT ACTCCTCTCT CTCTGTCTCC
1001 AGGCAGAAAG GGAGAGAAAC AGAGGAGACA GAGAGGAGGA GAGAGACAGA GGGAGAGAGA GACAGAGGGG AAGAGAGGCA GAGAGGGAAA GAGGCAGAGA
    TCCGTCTTTC CCTCTCTTG TCTCCTCTGT CTCTCCCTCT CTCTCTGTCT CCCCCTCTCT CCGTCTCTCT TTCTCTCCGT CTCTCCCTTT CTCCGTCTCT
1101 AGGAAAGAGA CAGGAGAGGA AGGAGAGAGG CAGAGAGGGA GAGAGGCAGA GAGGGAGAGA GAGGAGAGGA CACAGAGGGA GAGAGGGACA GAGAGAGATA
    TCCTTTCTCT GTCCGTCTCT TCCTCTCTCC GTCTCTCCCT CTCTCCGTCT CTCCCTCTCT CCGTCTCTCT GTCTCTCCCT CTCTCCCTGT CTCTCTCTAT
1201 GAGCAGGAGG TCGGGGCACT CTGAGTCCCA GTTCCCAGTG CAGCTGTAGG TCGTCATCAC CTAAACACAC GTCAATATAA GTCCTCGTGC CTGCTGCTCA
    CTCGTCTCTC AGCCCCGTGA GACTCAGGGT CAAGGGTCAC GTCGACATCC AGCAGTAGTG GATTGTGTG CACGTTATTT CAGGAGCAGG GACGACGAGT
1301 CAGCCCCCGA GAGCCCCCTCC TCCTGGAGAA TAAACCTTT GGCAGCTGCC CTTCTCAA AAAAATAAAA AAAAAA
    GTCGGGGGCT CTCGGGGAGG AGGACCTCTT ATTTGGAA CCGTCGACGG GAAGGAGTT TTTTTTTTTT TTTTTT
```

FIG. 1B



USES OF AGONISTS AND ANTAGONISTS TO MODULATE
ACTIVITY OF TNF-RELATED MOLECULES

Sheet 3 of 29

1 AAGACTCAAA CTTAGAAACT TGAATTAGAT GTGGTATTCA AATCCTTACG TGCCGCGAAG ACACAGACAG CCCCCGTAAG AACCCACGAA GCAGGCGAAG GCAGGCGCTT
TTCTGAGTTT GAATCTTTGA ACTTAATCTA CACCATAAGT TTAGGAATGC ACGGCGCTTC TGTGTCTGTC GGGGGCATTC TTGGGTGCTT CGTCCGCTTC

101 TTCATTGTTT TCAACATTCT AGCTGCTCTT GCTGCATTGG CTCTGGAATT CTCTAGAGA TATTACTTGT CCTTCCAGGC TGTCTCTTCT GTAGCTCCCT
AAGTAACAAG AGTTGTAAGA TCGACGAGAA CGACGTAAAC GAGACCTTAA GAACATCTCT ATAATGAACA GGAAGGTCCG ACAAGAAAGA CATCGAGGGA

201 TGTTTTCTTT TTGTGATCAT GTTGCGATG GCTGGGCAGT GCTCCCAAAA TGAATATTTT GACAGTTTGT TGCATGCTTG CATACTTGT CAACTTCGAT
ACAAAAGAAA AACACTAGTA CAACGTCTAC CGACCCGTCA CGAGGGTTTT ACTTATAAAA CTGTCAACA ACGTACGAAC GTATGGAACA GTTGAAGCTA

1 Me tLeuGlnMet AlaGlyGlnC ysSerGlnAs nGluTyrPhe AspSerLeuL euHisAlaCy sileProCys GlnLeuArgC

301 GTTCTTCTAA TACTCTCTCT CTAACATGTC AGCGTTATTG TAATGCAAGT GTGACCAATT CAGTGAAGG AACGAATGCG ATTCTCTGGA CCTGTTTGGG
CAAGAAGATT ATGAGGAGGA GATTGTACAG TCGCAATAAC ATTACGTTCA CACTGGTTAA GTCACCTTCC TTGCTTACGC TAAGAGACCT GGACAAACCC

29 ysSerSerAs nThrProPro LeuThrCysG lnArgTyrCy sAsnAlaSer ValThrAsnS erValLysGl yThrAsnAla IleLeuTrpT hrCysLeuGl

401 ACTGAGCTTA ATAATTTCTT TGGCAGTTT TGGCTAATG TTTTGTCTAA GGAAGATAAG CTCTGAACCA CTCTGAGGAG AGTTTAAAAA CACAGGATCA
TGACTCGAAT TATTAAAGAA ACCGTCAAAA GCACGATTAC AAAAACGATT CCTTCTATTG GAGACTTGGT AATTTCTGTC TCAAAATTTT GTGCTCTAGT

62 yLeuSerLeu IleIleSerL euAlaValPh eValLeuMet PheLeuLeuA rgLysIleSe rSerGluPro LeuLysAspG luPheLysAs nThrGlySer

501 GGTCTCTCGG GCATGGCTAA CATTGACCTG GAAAGAGCA GGAAGTGTGA TGAATATTAT CTCTCGAGAG GCCTCGAGTA CACGGTGGAA GAATGCACCT
CCAGAGGACC CGTACCGATT GTAACTGGAC CTTTCTCTCGT CCTGACCACT ACTTTAATAA GAAGGCTCTC CGGAGCTCAT GTGCCACCTT CTTACGTGGA

95 GlyLeuLeuG lyMetAlaAs nIleAspLeu GluLysSerA rgThrGlyAs pGluIleIle LeuProArg lylLeuGluTy rThrValGlu GluCysThrC

601 GTGAAGACTG CATCAAGAGC AAACCGAAGG TCGACTCTGA CCATTGCTTT CCACCTCCAG CTATGGAGGA AGGCGCAACC ATTCTTGTCA CCACGAAAC
CACTTCTGAC GTAGTTCTCG TTGGCTTCC AGCTGAGACT GGTAAACGAA GGTGAGGTC GATACCTCCT TCCGCGTTGG TAAGAACAGT GGTGCTTTTG

129 ysGluAspCy sileLysSer LysProLysV alAspSerAs phiCysPhe ProLeuProA laMetGluGl uGlyAlaThr IleLeuValT hrThrLysTh

701 GAATGACTAT TGCAAGAGCC TGCCAGCTGC TTTGAGTGCT ACGGAGATAG AGAAATCAAT TTCTGCTAGG TAATTAACCA TTTCGACTCG AGCAGTGCCA
CTTACTGATA ACGTTCTCGG ACGGTGACG AACTCACGA TGCCTCTATC TCTTTAGTTA AAGACGATCC ATTAATTGGT AAAGCTGAGC TCGTCACGGT

162 rAsnAspTyr CysLysSerL euProAlaAl aleuSerAla ThrGluIleG luLysSerIl eSerAlaArg OC*

801 CTTTAAAAAT CTTTTGTGAG AATAGATGAT GTGTCAGATC TCTTTAGGAT GACTGTATTT TTCAGTTGCC GATACAGCTT TTTGTCTCTT AACTGTGGAA
GAAATTTTAA GAAAACAGTC TTATCTACTA CACAGTCTAG AGAAATCCTA CTGACATAAA AAGTCAACGG CTATGTCGAA AAACAGGAGA TTGACACCTT

901 ACTCTTTATG TTAGATATAT TTCTCTAGGT TACTGTTGGG AGCTTAATGG TAGAACTTC CTTGGTTTCA TGATTAAAGT CTTTTTTTTT CCTGA
TGAGAAATAC AATCTATATA AAGAGATCCA ATGACAACCC TCGAATTACC ATCTTTGAAG GAACCAAGT ACTAATTCA GAAAAAAA GGAAT

FIG. 2



USES OF AGONISTS AND ANTAGONISTS TO MODULATE
ACTIVITY OF TNF-RELATED MOLECULES

Sheet 4 of 29

1 ATGATGACT CCACAGAAAG GGAGCAGTCA GGCCTTACTT CTTGCCTTAA GAAAGAGAA GAAATGAAC TGAAGGAGTG TGTTCATC CTCCCACGGA
TACCTACTGA GGTGCTTTC CCTCGTCAGT GCGGAATGAA GAACGGAATT CTTTCTCTT CTTTACTTTG ACTTCCTCAC ACAAGGTAG GAGGGTGCCT
1 M D D S T E R E Q S R L T S C L K K R E E M K L K E C V S I L P R K
101 AGGAAGCCC CTCTGTCGA TCCTCAAAG ACGGAAAGCT GCTGGTGCA ACCTTGCTG TGGCACTGCT GTCTTGCTG CTCACGGTG TGTCTTCTA
TCCTTCGGG GAGACAGGCT AGGAGGTTTC TGCTTTTCGA CGACCGACGT TGAACGACG ACCGTGACGA CAGAAGCAG GAGTGCAC CAGAAAGAT
35 E S P S V R S S K D G K L L A A T L L L A L L S C C L T V V S F Y
201 CCAGTGGCC GGCCTGCAAG GGGACCTGGC CAGCCTCCG GAGAGCTGC AGGCCACCA CGCGGAGAAG CTGCCAGCAG GAGCAGGAGC CCCCAGGCC
GGTCCACCG GGGACGTTT CCTGGACCG GTCCGAGGCC CGTCTCAGC GTCGCTGCTT GCGCTCTTC GACGGTCGTC CTCGTCTCG GGGGTTCCGG
68 Q V A A L Q G D L A S L R A E L Q G H H A E K L P A G A G A P K A
301 GGCTTGAGG AAGCTCCAGC TGTCACCGC GACTGAAA TCTTTGAAC ACCAGCTCCA GGAGAAGCA ACTCCAGTCA GAACAGCAGA AATAAGCGTG
CCGAACCTCC TTCGAGGTCG ACAGTGGCG CCTGACTTTT AGAACTGG TGGTCGAGGT CCTCTCGT TGAGGTCAGT CTTGTCGTCT TTATTCGCAC
101 G L E E A P A V T A G L K I F E P P A P G E G N S S Q N S R N K R A
401 CCGTTCAGG TCAGAAGAA ACAGTCACTC AAGCTGCTT GCACTGATT GCAGACAGTG AAACACCAAC TATACAAAA GGATCTTACA CATTTGTTCC
GGCAAGTCCC AGGTCTTCTT TGTCAGTGAG TTCTGACGAA CGTTGACTAA CGTCTGTCAC TTTGTGGTTG ATATGTTTTT CCTAGAATGT GTAACAAAGG
135 V Q G P E E T V T Q D C L Q L I A D S E T P T I Q K G S Y T F V P
501 ATGGCTTCTC AGCTTTAAA GGGGAAGTGC CCTAGAAGAA AAAGAGAATA AAATATTGGT CAAAGAAACT GGTACTTTT TTATATATGG TCAGTTTTA
TACCGAAGAG TCGAAATTTT CCCCTTCAGG GATCTTCTT TTTCTCTAT TTTATAACCA GTTCTTTGA CCAATGAAAA AATATATACC AGTCCAAAT
168 W L L S F K R G S A L E E K E N K I L V K E T G Y F F I Y G Q V L
601 TATACTGATA AGACTACGC CATGGACAT CTAAATCAGA GGAAGAAGGT CCACTGCTTT GGGGATGAAT TGAGTCTGGT GACTTTGTTT CGATGTATTC
ATATGACTAT TCTGGATGCG GTACCCCTGTA GATTAAGTCT CCTTCTTCCA GGTACAGAAA CCCCTACTTA ACTCAGACCA CTGAAACAAA GCTACATAAG
201 Y T D K T Y A M G H L I Q R K K V H V F G D E L S L V T L F R C I Q
701 AAAATATGCC TGAACACTA CCCAATAAT CCTGCTATT CCTGCTATT GCAAACTGG AAGAAGGAGA TGAACCTCAA CTTGCAATAC CAAGAGAAA
TTTTATACCG ACTTTGTGAT GGGTTATTAA GGACGATAAG TCGACCGTAA CGTTTGACC TTCTTCTCT ACTTGAGGT GAACGTTATG GTTCTCTTT
235 N M P E T L P N N S C Y S A G I A K L E E G D E L Q L A I P R E N
801 TGCACAAATA TCACCTGGATG GAGATGTCAC ATTTTGTGGT GCATTGAAC TGCTGTGA
ACGTGTTTAT AGTGACCTAC CTCTACAGTG TAAAAACCA CGTAACCTTG ACGACACT
268 A Q I S L D G D V T F F G A L K L L O

FIG. 3



USES OF AGONISTS AND ANTAGONISTS TO MODULATE
ACTIVITY OF TNF-RELATED MOLECULES

Sheet 5 of 29

1 GGTACGAGC TTCCTAGAGG GACTGGAACC TAATCTCCT GAGGCTGAGG GAGGTGGAG GGTCTCAAGG CAACGTGGC CCCACGACG AGTGCCAGGA
CCATGCTCG AAGGATCTCC CTGACCTTGG ATTAGAGGA CTCCGACTCC CTCCACCTC CCAGAGTTCC GTTGGACCG GGTGCTGCC TCACGGTCTCT

101 GCACCTACAG TACCCTAGC TTGCTTTCCT CCTCCCTCCT TTTATTTTC AAGTTCCTTT TTATTTCTCC TTGCGTAACA ACCTTCTTCC CTTCTGCACC
CGTGATTGTC ATGGGAATCG AACGAAGGA GGAGGGAGGA AAAATAAAG TTCAAGGAAA AATAAGAGG AACGCATTGT TGAAGAAGG GAAGACGTGG

201 ACTGCCCCGA CCCTTACCCG CCCCGCCACC TCCTTGCTAC CCACCTCTTG AAACCAACAGC TGTTGGCAGG GTCCCCAGCT CATGCCAGCC TCATCTCCTT
TGACGGGCGCAT GGAATGGGC GGGCGGTGG AGGAACGATG GGTGAGAAC TTTGTTCTCG ACAACCGTCC CAGGGGTGGA GTACGGTGG AGTAGAGAA
M P A S S P F

301 TCTTGCTAGC CCCCAAGGG CCTCCAGGCA ACATGGGGG CCAGTCAGA GAGCCGGCAC TCTCAGTTGC CCTCTGTTG AGTTGGGGG CAGCTCTGGG
AGAACGATCG GGGGTTTCCC GAGGTCCGT TGTACCCCCC GGTTCAGTCT CTGCGCCGTG AGAGTCAACG GGAGACCAAC TCAACCCCCC GTCGAGACCC

8 L L A P K G P P G N M G G P V R E P A L S V A L W L S W G A A L G

401 GCGCGTGGCT TGTGCCATGG CTCTGCTGAC CCAACAACA GAGCTGCAGA GCCTCAGGAG AGAGGTGAGC CGGCTGCAGG GGACAGGAGG CCCCTCCCAG
CCGGCACCGA ACACGGTACC GAGACGACTG GGTGTTTGT CTCGACGCTC CGGAGTCTC TCTCCACTCG GCGGACGTC CCTGTCCTCC GGGGAGGTC

41 A V A C A M A L L T Q Q T E L Q S L R R E V S R L Q G T G G P S Q

501 AATGGGGAAG GGTATCCCTG GCAGAGTCTC CCGGAGCAGA GTTCGATGC CTGGAAGCC TGGAGAATG GGGAGAGATC CCGAAAAGG AGAGCAGTGC
TTACCCCTTC CCATAGGAGC CGTCTCAGAG GGCCTCGTCT CAAGCTACG GACCTTCGG ACCCTCTAC CCCTCTCTAG GGCCTTTTCC TCTCGTACG

74 N G E G Y P W Q S L P E Q S S D A L E A W E N G E R S R K R R A V L

601 TCACCCAAA ACAGAAGAG CAGCACTCTG TCCTGCACCT GGTTCACCT AACGCCACT CCAAGGATGA CTCCGATGTG ACAGAGTGA TGTGGCAACC
AGTGGGTTT TGTCTTCTC GTCGTGAGC AGGACGTGGA CCAAGGTGA TTGCGGTGA GGTTCCTACT GAGGTACAC TGCTCCACT ACACCGTTGG

108 T Q K Q K K Q H S V L H L V P I N A T S K D D S D V T E V M W Q P

701 AGCTCTTAGG CGTGGGAGG GCCTACAGG CCAAGGATAT GGTGTCGAA TCCAGGATGC TGGAGTTTAT CTGCTGTATA GCCAGTCTCT GTTCAAGAC
TCGAGAATCC GCACCTCTC CGGATGTCG GGTTCCTATA CCACAGCTT AGTCTCTACG ACCTCAAATA GAGACATAT CGGTCCAGGA CAAAGTTCTG

141 A L R R G R G L Q A Q G Y G V R I Q D A G V Y L L Y S Q V L F Q D

801 GTGACTTCA CCATGGTCA GGTGGTGTCT CGAGAAGGC AAGGAAGGA GAGACTCTA TTCCGATGA TAAGAATAT GCCCTCCAC CCGACCGGG
CACTGAAGT GGTACCCAGT CCACCACAGA GTCTTCCGG TTCTTCCGT CCTCTGAGAT AAGGTACAT ATTCTTATA CGGAGGGTG GGCCTGGCCC

174 V T F T M G Q V V S R E G Q G R Q E T L F R C I R S M P S H P D R A

901 CCTACACAG CTGCTATAGC GCAGGTGTCT TCCATTACA CCAAGGGAT ATTCTGAGT TCATAATTC CCGGGCAAGG GCGAACTTA ACCTCTCTCC
GGATGTTGTC GAGCATATCG CGTCCACAGA AGGTAATGT GGTTCCTATA TAAGACTCAC AGTATTAGG GGCCGTTCC CGCTTTGAAT TGGAGAGAGG

208 Y N S C Y S A G V F H L H Q G D I L S V I I P R A R A K L N L S P

FIG. 4A



1001 ACATGGAACC TTCCTGGGT TTGTGAACT GTGATTGTGT TATAAAGT GGTCCCAGC TTGGAAGACC AGGTGGGTA CATACTGGAG ACAGCCAAGA
TGTAACCTTGG AAGGACCCCA AACACTTGA CACTAACACA ATATTTTCA CCGAGGGTCG AACCTTCTGG TCCCACCCAT GTATGACCTC TGTCGGTTCT
241 H G T F L G F V K L O
1101 GCTGAGTATA TAAAGGAGAG GGAATGTGA CATCTTCTCTG GGTTCGCTC CCGTTCTCTC ACTTTTCCCT TTTCATTCCC ACCCCCTAGA
CGACTCATAT ATTTCTCTC CTTTACAGT CCTTGCTCC GTAGAAGGAC CCAACCGAG GGCACAGGAG TGAAGAGGGA AAAGTAAGGG TGGGGGATCT
1201 CTTTGATTTT ACGGATATCT TGCTTCTGTT CCCATGGAG CTCCGAATTC TTGCGTGTGT GTAGATGAG GGGGGGGGAC GGGCGCAGG CATTTGTTCTAG
GAACTAATA TGCCATAGA ACGAAGACAA GGGGTACCTC GAGGCTTAAG AACGCACACA CATCTACTCC CCGCCCCCTG CCGCGGTCC GTAACAAGTC
1301 ACCTGGTCGG GGGCCACTGG AAGCATCCAG AACAGCACCA CCATCTTA
TGGACCAGCC CCGGGTGACC TTCGTAGGTC TTGTCGTGGT GGTAAGAT

FIG. 4B



PRO	XXXXXXXXXXXXXXXXXX	(Length = 15 amino acids)
Comparison Protein	XXXXXXYYYYYYY	(Length = 12 amino acids)

% amino acid sequence identity =

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =

5 divided by 15 = 33.3%

FIG. 5A

PRO	XXXXXXXXXXXX	(Length = 10 amino acids)
Comparison Protein	XXXXXXYYYYYYZZYZ	(Length = 15 amino acids)

% amino acid sequence identity =

(the number of identically matching amino acid residues between the two polypeptide sequences as determined by ALIGN-2) divided by (the total number of amino acid residues of the PRO polypeptide) =

5 divided by 10 = 50%

FIG. 5B



htACI(265) htACI	10 M S G L G R S R R G G R S R V D Q E E R F P Q G L W T G V A M R S C P E E Q Y W D P L L G T C M S C M S G L G R S R R G G R S R V D Q E E R F P Q G L W T G V A M R S C P E E Q Y W D P L L G T C M S C	20 30 40 50
htACI(265) htACI	60 K T I C N H Q S Q R T C A A F C R S L S C R K E Q G K F Y D H L L R D C I S C A S I C G Q H P K Q C K T I C N H Q S Q R T C A A F C R S L S C R K E Q G K F Y D H L L R D C I S C A S I C G Q H P K Q C	70 80 90 100
htACI(265) htACI	110 A Y F C E N K L R S P V N L P P E L R R Q R S G E V E N N S D N S G R Y Q G L E H R G S E A S P A L A Y F C E N K L R S P V N L P P E L R R Q R S G E V E N N S D N S G R Y Q G L E H R G S E A S P A L	120 130 140 150
htACI(265) htACI	160 P G L K L S A D Q V A L V Y S T L G L C L C A V L C C F L V A V A C F L K K R G D P C S C Q P R S R P G L K L S A D Q V A L V Y S T L G L C L C A V L C C F L V A V A C F L K K R G D P C S C Q P R S R	170 180 190 200
htACI(265) htACI	210 P R Q S P A K S S Q D H A M E A G S P V S T S P E P V E T C S F C F P E C R A P T Q E S A V T P G T P R Q S P A K S S Q D H A M E A G S P V S T S P E P V E T C S F C F P E C R A P T Q E S A V T P G T	220 230 240 250
htACI(265) htACI	260 P D P T C A G R T - - - - - T T R T T V L Q P C P H I P D S G L G I V C V - - - - - P R E G - - - - - Z P D P T C A G R W G C H T R T T V L Q P C P H I P D S G L G I V C V - - - - - P R E G - - - - - Z	270 280 290 300

FIG. 6




FIG. 7

FIG. 8A







FIG. 8B



Ip:with protein A
WB with α Flag HR

FIG. 8C

FIG. 8D





FIG. 8F

FIG. 8E



Ip: with
 α Flag
WB: with
 α HulgG. HRP




FIG. 8G




FIG. 8H

FIG. 9A

Blys/
TALL-1





FIG. 9B

TACI

BCMA

Vector







FIG. 10





120203

13146 U.S. PTO




FIG. 11C




FIG. 11D




FIG. 12A




FIG. 12B




FIG. 12C




FIG. 13A




FIG. 13B

13146 U.S. PTO
120203




FIG. 14A



Summary of anti-April mABs

mAb	Isotype	Epitope	Binding (ELISA) April	TALL	Block April binding to BCMA	TACI
3C6.4.2	IgG2a	C	++	-	+++	+
5E8.7.4	IgG2a	A	++	-	-	-
5E11.1.2	IgG1	C?	++	-	+	+
5G8.2.2	IgG2a	B	++	-	-	-

MAb 5E11.1.2 may bind to the similar epitope.

FIG. 14B




FIG. 15A




FIG. 15B




FIG. 15C




FIG. 15D








FIG. 17C



FIG. 17D



FIG. 17A



FIG. 17B

120203

13146 U.S. PTO




FIG. 17E



FIG. 17F




FIG. 18C




FIG. 18B




FIG. 18A




FIG. 18E




FIG. 18D




FIG. 19B




FIG. 19A



TACI-Fc treatment of mice inhibits EAE in MBP-TCR transgenic mice

